Cover Image

Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German testicular cancer study group case series

Outcomes of multiply relapsed, refractory germ-cell tumour (GCT) patients remain poor with an overall survival (OS) of a few months only. Thus, new therapeutic advances are urgently needed. Cabazitaxel has shown preclinical activity in platinum-resistant GCT models. Here, we report the first clinica...

Full description

Saved in:
Bibliographic Details
Main Authors: Oing, Christoph (Author) , Hentrich, Marcus (Author) , Lorch, Anja (Author) , Gläser, Dietrich (Author) , Rumpold, Holger (Author) , Ochsenreither, Sebastian (Author) , Richter, Stephan (Author) , Dieing, Annette (Author) , Zschäbitz, Stefanie (Author) , Pereira, Ronnie Rodrigues (Author) , Bokemeyer, Carsten (Author) , Seidel, Christoph (Author)
Format: Article (Journal)
Language:English
Published: 2020
In: Journal of cancer research and clinical oncology
Year: 2019, Volume: 146, Issue: 2, Pages: 449-455
ISSN:1432-1335
DOI:10.1007/s00432-019-03071-2
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00432-019-03071-2
Get full text
Author Notes:Christoph Oing, Marcus Hentrich, Anja Lorch, Dietrich Gläser, Holger Rumpold, Sebastian Ochsenreither, Stephan Richter, Annette Dieing, Stefanie Zschäbitz, Ronnie Rodrigues Pereira, Carsten Bokemeyer, Christoph Seidel
Description
Summary:Outcomes of multiply relapsed, refractory germ-cell tumour (GCT) patients remain poor with an overall survival (OS) of a few months only. Thus, new therapeutic advances are urgently needed. Cabazitaxel has shown preclinical activity in platinum-resistant GCT models. Here, we report the first clinical case series of cabazitaxel treatment for platinum-refractory GCT.
Item Description:Published: 14 December 2019
Gesehen am 24.06.2020
Physical Description:Online Resource
ISSN:1432-1335
DOI:10.1007/s00432-019-03071-2

Similar Items